文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

估算在73个受Gavi支持的国家中疫苗接种对耐抗菌药物伤寒热的影响:一项数学建模研究

Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study.
PubMed 文献 · Lancet Infect Dis · 2022-02-03

该数学建模研究结合伤寒传播模型与荟萃分析得到的抗菌药物耐药估计,预测在73个符合Gavi支持条件的低收入国家中,接种伤寒结合疫苗(TCV)对耐抗菌药物伤寒热负担的影响。预测在9月龄常规接种TCV并开展至15岁补种活动,可避免46%–74%的伤寒热病例,并将耐抗菌药物伤寒热的相对患病率降低16%(95%预测区间0–49)。

要点

  • 9月龄常规接种TCV联合至15岁补种,预测可避免73国46%–74%的伤寒热病例。
  • 接种预测使耐抗菌药物伤寒热相对患病率降低16%(95%PI 0–49)。

核心结论

  • 结果表明,优先在耐抗菌药物伤寒热可避免负担高的国家引入TCV具有益处。

研究设计与样本

  • 数学建模研究,将伤寒传播模型输出与荟萃分析的抗菌药物耐药估计相结合。
  • 预测范围覆盖73个符合Gavi支持条件的低收入国家,分别考虑氟喹诺酮不敏感和多药耐药。
  • 基于疫苗覆盖率预测评估接种效果,并探索关键模型参数对耐药患病率影响的变化。

主要发现

  • 9月龄常规接种TCV并开展至15岁补种活动,预测可避免73国全部伤寒热病例的46%–74%。
  • 接种预测使耐抗菌药物伤寒热相对患病率降低16%(95%预测区间0–49)。

临床怎么用

  • 作者认为,结果支持优先在耐抗菌药物伤寒热可避免负担高的国家引入TCV。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multidrug resistance and fluoroquinolone non-susceptibility (FQNS) are major concerns for the epidemiology and treatment of typhoid fever. The 2018 prequalification of the first typhoid conjugate vaccine (TCV) by WHO provides an opportunity to limit the transmission and burden of antimicrobial-resistant typhoid fever. METHODS: We combined output from mathematical models of typhoid transmission with estimates of antimicrobial resistance from meta-analyses to predict the burden of antimicrobial-resistant typhoid fever across 73 lower-income countries eligible for support from Gavi, the Vaccine Alliance. We considered FQNS and multidrug resistance separately. The effect of vaccination was predicted on the basis of forecasts of vaccine coverage. We explored how the potential effect of vaccination on the prevalence of antimicrobial resistance varied depending on key model parameters. FINDINGS: The introduction of routine immunisation with TCV at age 9 months with a catch-up campaign up to age 15 years was predicted to avert 46-74% of all typhoid fever cases in 73 countries eligible for Gavi support. Vaccination was predicted to reduce the relative prevalence of antimicrobial-resistant typhoid fever by 16% (95% prediction interval [PI] 0-49). TCV introduction with a catch-up campaign was predicted to avert 42·5 million (95% PI 24·8-62·8 million) cases and 506 000 (95% PI 187 000-1·9 million) deaths caused by FQNS typhoid fever, and 21·2 million (95% PI 16·4-26·5 million) cases and 342 000 (95% PI 135 000-1·5 million) deaths from multidrug-resistant typhoid fever over 10 years following introduction. INTERPRETATION: Our results indicate the benefits of prioritising TCV introduction for countries with a high avertable burden of antimicrobial-resistant typhoid fever. FUNDING: The Bill & Melinda Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Birger R, Antillón M, Bilcke J, et al. Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. Lancet Infect Dis. 2022. PMID: 35123673. doi:10.1016/S1473-3099(21)00627-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。